4/21/04

		s sign (+) inside thi work Reduction Ac		L		Patent and Tredem	proved for use through 10/31/99. OMB 0551-0031 ank Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid CMB control number.	4
(	Substil	tute for form 1449A	VPTO			C	omplete if Known	1
						Application Number	Not Yet Known	
	INF	ORMATIC	ואכ	DIS	SCLOSURE	Filing Date	Herewith	Ì
- 1	ST	ATEMENT	ГВ١	/ A	PPLICANT	First Named Inventor	WEICHERT	ĺ
- 1						Group Art Unit	1624	ĺ
L		(use as many	sheel	S 83	necessary)	Examiner Name	T. TRUONG	7
- (	Sheet	1		of	2	Attorney Docket Number	DEAV2003/0029 - US - NP	i

			8 10	U.S. PATENT DOCL	Class/subclass			
Examiner	Cite No.1	U.S. Patent Document		Name of Petentee or Applicant	Date of Publication of	Rapes Cohemer, thes,		
Initials'		Number	Kind Code <sup>2</sup> (il known)	of Cited Document	Cited Document MM-DD-YYYY	- Where Relevant - Passague or Relevant - Flouree Appears		
711		10/146671		GARVEY, et al.	05-16-2002			
44	$\checkmark$	6,617,359		STROBEL	09-09-2003	514/617		
411		10/73160		STROBEL	02-13-2002			
1		10/73203		STROBEL	02-13-2002			
an		10/73307		STROBEL	02-13-2002			
$\rightarrow$			_	·				
					<u> </u>	•		
<b></b> ↓								
$\rightarrow$			$\dashv$					

					EIGN PATENT DOCUMENT	rs		
Examiner nitials*	Cite No.1	Office	Foreign Patent Do Number <sup>4</sup>	Cument Kind Code <sup>1</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Cohumns, Lines, Where Relevant Passages or Relevant Figures Appear	71
M	<u>/</u>	wo	WO 00/03746		LIAO	01-27-2000		Т
MI		wo	WO 99/47153		LIAO	09-23-1999		
								I
					<del> </del>			╁
								İ
-+					•	<del> </del>		╀
	111	ī				A		1
			7					L
	_/		my 1	dx	0	4/	9/06	
Examlı Signatı		_ /	-10			ate onsidered	15/05	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documenta, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (*) inside this box ->	PTO/SB/088 (10-95) Approved for use through 10/11/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449B/PTO	G	omplete if Known		
	Application Number	Not Yet Known		
INFORMATION DISCLOSURE	Filing Date	Herewith		
STATEMENT BY APPLICANT	First Named Inventor	WEICHERT		
OTATEMEN, BY ANY ENGAGE	Group Art Unit	1624		
(use as many sheets as necessary)	Examiner Name	T. TRUONE		

Sheet

of

2

2

Attorney Docket Number

DEAV2003/0029 - US - NP

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	th.					
TMT	/	DRIVER, et al., A Second-Generation Catalyst for Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdCl2, J. AMer. Chem Soc.; 118; 1996; pp.7217-7218.						
	/	ENDRES, et al., Stroke Protection By 3-Hydroxy-3-Methylglutaryl (HMG) - CoA Reductase Inhibitors Medicated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 95 (1998) 8880-8885,						
	1	LI Hulge et al., Activation of Protein Kinase C(alpha) and/or (epsilon) Enhances Transciption of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, Vol. 53, pp 630-637						
	V	MARTIN-SANTAMARIA, et al., Synthesis and Stereochemistry of 11,11a-Dihydro Derivatives of (45)-2,4-Dimethyl-2,4dihydro-1H-pyrazinc(2,1-b)quinazoline-3,6-diones. A New Transannular Rearrangement Proposal., J. Org.Chem.; 64; 1999; pp.7233-7235.						
	v	MOROI, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury In Mice, J. Clin. Invest., 101 (1998) 1225-1232						
		NAKAYAMA Masafumi et al., T-785>C Mutation in the 5'-Flanking Region of the Endothetial Ntric Oxide Synthase Gene is Associated with Coronary Spasm, Clinical Investigation and Reports, Circulation 99, 1999, pp 2864-2870						
	/	SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research 74 (1994) 349-353						
	- /	VARENNE, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 11 (2000) 1329-1339 ,						
MT	/	NOJKOVSKY, et al., Solid-Phase Synthesis of Heterocycles Containing an 1-Acyl-3-oxopiperazine Skeleton, J. Org. Chem.; 63; 1998; pp. 3162-3163.						

Examiner	110 -	Date	1-	1
Signature	won	Considered	5181	(4)
		00.00.00		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5.08

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.